The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up

Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up

July 10, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Within seven years of diagnosis, 13–24% of patients with juvenile idiopathic arthritis (JIA) will develop JIA-associated uveitis, a condition that may be effectively treated with adalimumab. Adalimumab was approved in Europe for the treatment of JIA-associated uveitis based on the results of the SYCAMORE trial. This randomized, placebo-controlled trial took place in 17 centers in the U.K. and showed clear therapeutic benefit of adalimumab for the treatment of JIA-associated uveitis. One center reported longer term outcomes in patients enrolled in the SYCAMORE trial, including visual acuity, safety and disease activity.

You Might Also Like
  • Adalimumab + Methotrexate Effective for Uveitis in JIA
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
Also By This Author
  • T Cell Exhaustion: A New Strategy for Treating Autoimmune Disease

The Bristol Center contributed 31% of the total SYCAMORE cohort. Investigators in Bristol report that, although patients with JIA-associated uveitis tolerated treatment with adalimumab and experienced excellent visual acuity outcomes, drug-induced remission of JIA-associated uveitis did not persist once the drug was stopped after one to two years of treatment.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Sarah Horton, MD, honorary senior research associate of the Bristol Eye Hospital, U.K., and colleagues published the five-year, follow-up study of the Bristol participants of the SYCAMORE trial June 12 in the American Journal of Ophthalmology. The results of the retrospective interventional case series from the single trial center are consistent with a long-term role for adalimumab in the treatment of refractory JIA-associated uveitis.1

Investigators in Bristol randomized 28 patients in the SYCAMORE trial to receive adalimumab and methotrexate (n=19) or placebo and methotrexate (n=9). Twelve patients in the adalimumab arm and one patient in the placebo arm completed the trial. The SYCAMORE trial protocol included withdrawal of adalimumab—but not methotrexate—for all participants. The mean age at the final SYCAMORE visit was 10.25 years (standard deviation of 4.49), and 72% of the children were female.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The follow-up period began after adalimumab was stopped and included 81.62 total patient years, during which 26 of the 28 patients experienced a flare of their JIA-associated uveitis. During that time, 23 patients opted for adalimumab treatment for their active JIA-associated uveitis. Twenty-seven of the 28 Bristol participants demonstrated no unexplained or sustained reduction. Four participants developed a cataract during the extended study period, and one participant experienced a reduction in vision due to the cataract. The mean visual acuity for the remaining 27 participants was -0.04 (right eye) and -0.05 (left eye).

All children continued methotrexate through the end of the follow-up period. However, five patients stopped adalimumab during this time. Two patients stopped because of ineffectiveness, and three in response to a two-year period of disease inactivity. The children who stopped adalimumab did so suddenly, and the question remains whether there is a more appropriate approach to withdrawing adalimumab.

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: adalimumab, JIA, juvenile idiopathic arthritis (JIA), Uveitis

You Might Also Like:
  • Adalimumab + Methotrexate Effective for Uveitis in JIA
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • Treating Uveitis with Adalimumab Improves Quality of Life

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)